– SomaLogic partners with Dante Genomics to improve clinical and research adoption of proteomics in Europe
SomaLogic’s 7000 plex SomaScan® platform will be used in Europe-wide proteomics tests.
BOULDER, Colo. and L’AQUILA, Italy, July 24, 2023 /PRNewswire/ — SomaLogic Operating Co. Inc., (Nasdaq:SLGC), a leader in data-driven proteomics technology, today announced its partnership with Dante Genomics, a world leader in genomics and precision medicine, to offer a comprehensive solution for European-scale proteomics testing. Dante will be the first authorized SomaLogic site in Italy.
“For the past seven years, Dante has been intensely focused on improving the clinical utility of the genome, and by partnering with SomaLogic, we will now work together to enhance proteome research and discovery capabilities,” said Andrea Riposati, Co-Founder and CEO of Dante Genomics. “By combining proteomics and genomics, we will develop clinical insights and actionable results. We are excited about the future of multiomics, where partnerships like this will mean better overall healthcare for more people around the world.”
Dante Genomics will run SomaLogic’s technology from its laboratory in Italy, providing proteomics services for the European market. SomaLogic’s 7,000 plex SomaScan® platform can be applied in research and discovery. You can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample.
SomaLogic and Dante Genomics will partner to deliver one of the first multi-omics capabilities to support clinical research discovery, expanding the databases and total addressable market for both companies.
“Italy is a leader in life sciences research in Europe and shows promising growth in omics research in the academic and private sectors,” said SomaLogic CEO Adam Taich. “We are excited to support Dante Genomics’ vision to accelerate clinical proteomics research.”
For more than 20 years, SomaLogic has grown from its roots in the research lab to become a world leader in proteomics with technology that delivers the quality and quantity of biological insights life science researchers need, from the lab to the last mile.
About Dante Genomics
Dante Genomics is a global genomics information company creating and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and software. The company uses its platform to deliver better patient outcomes, prevention, improved diagnostics, and personalized medicine. The company’s assets include one of the largest private genomic databases with research consent, proprietary software designed to unleash the power of genomic data at scale, and proprietary processes that enable an industrial approach to genomic sequencing.
About SomaLogic
SomaLogic is catalyzing drug research and development and biomarker identification as a world leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 7,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body and twice as many as other proteomic platforms. For more than 20 years, we have supported pharmaceutical companies and contract research and academic organizations that rely on our protein detection and analysis technologies to drive drug, disease and treatment discoveries in areas such as oncology, diabetes, cardiovascular, liver and metabolic diseases. Learn more at www.somalogic.com and follow @somalogic on LinkedIn.
forward-looking statements
This press release contains certain forward-looking statements within the meaning of the “safety” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, except statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and management objectives are forward-looking statements. These forward-looking statements are generally identified by the words “believe”, “project”, “forecast”, “guidance”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “chance”, “plan”, “may”, “should”, “will”, “would”, “continue”, “probably will result”, “possible”, “potential”, “predict”, “pursue”, “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, without limitation, the factors described in Part I, Item 1A: “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These presentations identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to place undue reliance on any forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or if any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company does not and will not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
Dante Genomics Contact Laura D’AngeloVice President of Investor Relations ir@dantelabs.com 39 0862 191 0671 www.dantegenomics.com
SomaLogic Media Contact Emilia Costales 720-798-5054 ecostales@somalogic.com
SomaLogic Investor Contact Marissa BychGilmartin Group LLCinvestors@somalogic.com
Logo – https://mma.prnewswire.com/media/2035834…
Logo – https://mma.prnewswire.com/media/2159924…
View original content: https://www.prnewswire.com/news-releases/somalogic-se-asocia-con-dante-genomics-para-mejorar-la-adopcion-clinica-y-de-investigacion-de-la-proteomica-301883827.html
